Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2015 by Mayo Clinic
Sponsor:
Collaborators:
Information provided by (Responsible Party):
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01003769
First received: October 28, 2009
Last updated: July 27, 2015
Last verified: July 2015

October 28, 2009
July 27, 2015
September 2013
March 2018   (final data collection date for primary outcome measure)
  • Maximum tolerated dose of lenalidomide when given in combination with AT-101, defined as the dose level below the lowest dose that induces dose limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients) (Phase I) [ Time Frame: Up to day 28 of course 2 ] [ Designated as safety issue: Yes ]
  • Overall response rate (complete response [CR], CR with incomplete marrow recovery, clinical CR, nodular partial response [PR], and PR) (Phase II) [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
    The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.
  • Overall response rate including (CR & PR)of lenalidomide in combination with AT-101 at 6 month s and then 12 months [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Determine the maximum tolerated dose of lenalidomide in combination with AT-101 [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01003769 on ClinicalTrials.gov Archive Site
  • Incidence of adverse events, graded according to the Grading Scale for Hematologic Adverse Events in CLL Studies (Phase I) [ Time Frame: Up to 2 years ] [ Designated as safety issue: Yes ]
    The number and severity of all adverse events (overall and by dose-level) will be tabulated and summarized in this patient population. The grade 3+ adverse events will also be described and summarized in a similar fashion.
  • Incidence of toxicity, defined as adverse events classified as possibly, probably, or definitely related to study treatment, graded according to the Grading Scale for Hematologic Adverse Events in CLL Studies or ordinal Common Toxicity Criteria (Phase I) [ Time Frame: Up to 2 years ] [ Designated as safety issue: Yes ]
    Overall toxicity incidence as well as toxicity profiles by dose level, patient and tumor site will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.
  • Overall response rate (Phase II) [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]
    The proportion of responses by 6 months will be estimated by the number of patients who achieve a response by 6 months divided by the total number of evaluable patients. The proportion of responses by 12 months will be estimated in a similar manner. Exact binomial 95% confidence intervals for the true success proportions will be calculated.
  • Time to progression (Phase II) [ Time Frame: The time from registration to the earliest date of documentation of disease progression, assessed up to 2 years ] [ Designated as safety issue: No ]
    The distribution of time to progression will be estimated using the method of Kaplan-Meier.
  • Incidence of adverse events, graded according to the Grading Scale for Hematologic Adverse Events in CLL Studies (Phase II) [ Time Frame: Up to 30 days after the last day of study treatment ] [ Designated as safety issue: Yes ]
    The maximum grade for each type of adverse event, regardless of causality, will be recorded and reported for each patient, and frequency tables will be reviewed to determine adverse event patterns.
  • To evaluate the safety of the combination of lenalidomide and AT-101 in patients with relapsed or refractory B-CLL [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Time to progression (TTP)for the combination of Lenalidomide and AT-101 [ Time Frame: Until time of Disease progression ] [ Designated as safety issue: No ]
  • Conduct correlative studies for further understanding of the mechanism of antitumor activity of lenalidomide and AT-101 [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Change in T cell levels in peripheral blood [ Time Frame: Baseline to up to day 1 of course 2 ] [ Designated as safety issue: No ]
    To determine the effect of lenalidomide on the immune effector arm, immune function will be evaluated before and during treatment by assessing T and natural killer (NK) cell quantification in both peripheral blood and bone marrow. Changes in these values over time will be both graphically and quantitatively summarized and explored. In addition, these values will be explored in relation to response (responder vs non-responder as well as by quality of response, i.e. CR vs PR).
  • Change in NK cell levels in peripheral blood [ Time Frame: Baseline to up to day 1 of course 2 ] [ Designated as safety issue: No ]
    To determine the effect of lenalidomide on the immune effector arm, immune function will be evaluated before and during treatment by assessing T and NK cell quantification in both peripheral blood and bone marrow. Changes in these values over time will be both graphically and quantitatively summarized and explored. In addition, these values will be explored in relation to response (responder vs non-responder as well as by quality of response, i.e. CR vs PR).
  • Change in molecular target values by Western blot analysis of peripheral blood [ Time Frame: Baseline to up to day 1 of course 3 ] [ Designated as safety issue: No ]
    Specific molecular targets will be evaluated on peripheral blood by western blot analysis before and during treatment. Changes in these values over time will be both graphically and quantitatively summarized and explored.
Not Provided
 
Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia
A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)

This phase I/II trial studies the side effects and best dose of lenalidomide when given together with R-(-)-gossypol acetic acid and to see how well they work in treating patients with B-cell chronic lymphocytic leukemia (B-CLL) that has returned after a period of improvement (relapsed). Biological therapies, such as lenalidomide, may stimulate the immune system to attack cancer cells. R-(-)-gossypol acetic acid may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and causing the cells to die. Giving lenalidomide with R-(-)-gossypol acetic acid may be an effective treatment for relapsed or refractory B-CLL.

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) of lenalidomide in combination with AT-101 (R-(-)-gossypol acetic acid). (Phase I) II. To assess the overall response rate of lenalidomide in combination with AT-101. (Phase II)

SECONDARY OBJECTIVES:

I. To assess the overall response rates of lenalidomide in combination with AT-101 at 6 months and 12 months.

II. To evaluate time to progression (TTP) for the combination of lenalidomide + AT-101.

III. To evaluate the safety of this combination in patients with relapsed B-CLL.

TERTIARY OBJECTIVES:

I. To conduct correlative studies for further understanding of the mechanism of antitumor activity of lenalidomide and lenalidomide + AT-101.

OUTLINE: This is a phase I dose-escalation study of lenalidomide followed by a phase II study.

Patients receive lenalidomide orally (PO) once daily (QD) on days 1-21. Beginning in course 3, patients also receive AT-101 PO twice daily (BID) on days 1-3. Treatment repeats every 28 days for up to 11 courses (49-56 days for course 12 or last course of treatment) in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days and then every 3 months for up to 2 years.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Recurrent Chronic Lymphocytic Leukemia
  • Drug: Lenalidomide
    Given PO
    Other Names:
    • CC-5013
    • CC5013
    • CDC 501
    • IMiD-1
  • Drug: R-(-)-Gossypol Acetic Acid
    Given PO
    Other Names:
    • (-)-Gossypol Acetic Acid
    • AT-101
  • Other: Laboratory Biomarker Analysis
    Correlative studies
Experimental: Treatment (lenalidomide in combination with AT-101)
Patients receive lenalidomide PO QD on days 1-21. Beginning in course 2, patients also receive AT-101 PO BID on days 1-3. Treatment repeats every 28 days for up to 11 courses (49-56 days for course 12 or last course of treatment) in the absence of disease progression or unacceptable toxicity.
Interventions:
  • Drug: Lenalidomide
  • Drug: R-(-)-Gossypol Acetic Acid
  • Other: Laboratory Biomarker Analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
Not Provided
March 2018   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Understand and voluntarily sign an informed consent form
  • Able to adhere to the study visit schedule and other protocol requirements
  • Diagnosis of B-CLL, confirmed by flow cytometric analysis and as per the criteria outlined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL)/Hallek December 2008
  • Any prior therapy for B-CLL must have been discontinued >= 28-days prior to registration
  • Patients must have absolute lymphocyte counts (ALC) of more than 5,000 cell/mm^3
  • During phase I: all patients with relapsed disease will be eligible if they have received at least 1 prior standard CLL therapy and no more than 4 prior therapies (one of which must be a purine analog and/or an alkylating agent)
  • During phase II: all patients with relapsed disease will be eligible if they have received a minimum of 1 prior standard therapy and a maximum of 2 prior treatments (one of which must be a purine analog and/or an alkylating agent) for B-CLL and have developed relapse disease

    • Note: patients who have refractory disease (defined as - progressive disease on last treatment, or less than 6 months of clinical response to the last treatment) will not be eligible
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at registration
  • Absolute neutrophil count >= 1500/mm^3
  • Platelet count >= 30,000/mm^3
  • Serum creatinine =< 1.5 x upper limit of normal (ULN)
  • Total bilirubin =< 1.5 mg/dL or direct bilirubin =< 1.0 mg/dL for patients with Gilberts syndrome
  • Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2 x ULN or =< 5 x ULN if hepatic disease is present
  • Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL 10-14 days prior to and again within 24 hours before starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy; all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure

    • A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist
  • Patient must require treatment for symptomatic B-CLL as defined by the by the IWCLL/Hallek, December 2008 criterion or as determined clinically necessary by the treating physician
  • Willing to provide blood and baseline bone marrow aspirate samples for correlative research purposes

Exclusion Criteria:

  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
  • Pregnant or lactating females
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • Use of any other experimental drug or therapy =< 28 days prior to registration
  • Known hypersensitivity to thalidomide or lenalidomide
  • The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
  • Patients with of history of any other cancer (except nonmelanoma skin cancer or carcinoma in-situ of the cervix, unless in complete remission and off therapy for that disease for > 3 years)
  • Patient with history of cardiac arrest within the past 6 months
  • Patients with history of prior bowel resection, malabsorption syndrome, inflammatory bowel disease, prior bowel obstruction (partial or complete), Crohn disease, or any other disease significantly affecting the gastrointestinal tract
  • Prior use of gossypol or AT-101
Both
18 Years and older
No
United States
 
NCT01003769
MC128A, NCI-2009-01569, MC128A, P30CA015083, 3938
Yes
Mayo Clinic
Mayo Clinic
  • National Cancer Institute (NCI)
  • FDA Office of Orphan Products Development
Principal Investigator: Asher Chanan-Khan Mayo Clinic in Florida
Mayo Clinic
July 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP